Revolution Medicines Inc (OQ:RVMD)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 700 Saginaw Dr
REDWOOD CITY CA 94063-4752
Tel: 1-415-6757401
Website: https://www.revmed.com
IR: See website
<
Key People
Mark A. Goldsmith
Chairman of the Board, President, Chief Executive Officer
Jack Lee Anders
Chief Financial Officer
Steve Kelsey
President - Research and Development
Margaret A. Horn
Chief Operating Officer
Xiaolin Wang
Executive Vice President - Clinical Development
Jeff Cislini
Senior Vice President, General Counsel, Company Secretary
Alicia Gardner
Senior Vice President - Commercial
Lin Wei
Chief Medical Officer
 
Business Overview
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company's RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.
Financial Overview
For the three months ended 31 March 2024, Revolution Medicines Inc revenues decreased from $7M to $0K. Net loss increased 70% to $116M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 70% to $107.8M (expense), General and administrative - Balancing increase of 83% to $16.9M (expense).
Employees: 411 as of Mar 31, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $4,442M as of Mar 31, 2024
Annual revenue (TTM): $4.57M as of Mar 31, 2024
EBITDA (TTM): -$546.34M as of Mar 31, 2024
Net annual income (TTM): -$484.27M as of Mar 31, 2024
Free cash flow (TTM): -$457.88M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 164,986,227 as of May 2, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.